| Literature DB >> 25096877 |
Ashley T Tucker1, Emily M Nowicki1, Joseph M Boll1, Gregory A Knauf1, Nora C Burdis1, M Stephen Trent, Bryan W Davies2.
Abstract
Rates of infection with hospital-acquired Acinetobacter baumannii have exploded over the past decade due to our inability to limit persistence and effectively treat disease. A. baumannii quickly acquires antibiotic resistance, and its genome encodes mechanisms to tolerate biocides and desiccation, which enhance its persistence in hospital settings. With depleted antibiotic options, new methods to treat A. baumannii infections are desperately needed. A comprehensive understanding detailing A. baumannii cellular factors that contribute to its resiliency at genetic and mechanistic levels is vital to the development of new treatment options. Tools to rapidly dissect the A. baumannii genome will facilitate this goal by quickly advancing our understanding of A. baumannii gene-phenotype relationships. We describe here a recombination-mediated genetic engineering (recombineering) system for targeted genome editing of A. baumannii. We have demonstrated that this system can perform directed mutagenesis on wide-ranging genes and operons and is functional in various strains of A. baumannii, indicating its broad application. We utilized this system to investigate key gene-phenotype relationships in A. baumannii biology important to infection and persistence in hospitals, including oxidative stress protection, biocide resistance mechanisms, and biofilm formation. In addition, we have demonstrated that both the formation and movement of type IV pili play an important role in A. baumannii biofilm. Importance: Acinetobacter baumannii is the causative agent of hospital-acquired infections, including pneumonia and serious blood and wound infections. A. baumannii is an emerging pathogen and has become a threat to public health because it quickly develops antibiotic resistance, making treatment difficult or impossible. While the threat of A. baumannii is well recognized, our understanding of even its most basic biology lags behind. Analysis of A. baumannii cellular functions to identify potential targets for drug development has stalled due in part to laborious genetic techniques. Here we have pioneered a novel recombineering system that facilitates efficient genome editing in A. baumannii by single PCR products. This technology allows for rapid genome editing to quickly ascertain gene-phenotype relationships. To demonstrate the power of recombineering in dissecting A. baumannii biology, we use this system to establish key gene-phenotype relationships important to infection and persistence in hospitals, including oxidative stress protection, biocide resistance, and biofilm formation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25096877 PMCID: PMC4128354 DOI: 10.1128/mBio.01313-14
Source DB: PubMed Journal: MBio Impact factor: 7.867
Strains and plasmids
| Strain/plasmid | Relevant genotype and property | Source and/or reference |
|---|---|---|
| Strains | ||
| | Wild type | ATCC ( |
| | Wild type | ATCC |
| AT01 | This study | |
| AT02 | This study | |
| AT03 | This study | |
| AT04 | This study | |
| AT05 | This study | |
| AT06 | This study | |
| AT07 | This study | |
| AT08 | This study | |
| AT09 | This study | |
| AT10 | This study | |
| AT11 | This study | |
| AT12 | This study | |
| AT13 | This study | |
| AT14 | This study | |
| AT15 | This study | |
| AT16 | This study | |
| AT17 | This study | |
| AT18 | This study | |
| AT19 | This study | |
| AT20 | This study | |
| AT21 | This study | |
| AT22 | This study | |
| AT23 | This study | |
| AT24 | This study | |
| AT25 | This study | |
| AT26 | This study | |
| Plasmids | ||
| pMMB67EH | Ampr | ATCC ( |
| TOPO TA 2.1 | Kanr | Invitrogen |
| pKD4 | Kanr | |
| pWH1266 | Lab stock | |
| pBR322 | General cloning plasmid | Lab stock |
| pABBR_MCS | Ampr | This study |
| pAT01 | pMMB67EH with | This study |
| pAT02 | pMMB67EH with RecAb system | This study |
| pAT03 | pMMB67EH with FLP recombinase | This study |
| pAT04 | pMMB67EH with RecAb system, Tetr | This study |
| pAT05 | pABBR_MCS carrying | This study |
| pAT06 | pABBR_MCS carrying | This study |
| pAT07 | pABBR_MCS carrying | This study |
| pAT08 | pMMB67EH carrying | This study |
Deleted genes in this study
| Gene name | Gene location | Length (bp) | Locus tag | Accession no. |
|---|---|---|---|---|
| 1191086–1188755 | 2,331 | A1S_1030 | YP_001084064.1 | |
| A1S_1031 | YP_001084065.1 | |||
| Contig sidl23403laccninz.GG704573 | 2,576 | HMPREF0010_01568 | ||
| HMPREF0010_01569 | ||||
| LysR family transcriptional regulator | 2844859–2845533 | 675 | A1S_2456 | YP_001085476.1 |
| 2406038–2406508 | 471 | A1S_2063 | YP_001085092.1 | |
| 2039428–2036447 | 2,982 | A1S_1750 | YP_001084779.1 | |
| 1150365–1151153 | 789 | A1S_0992 | YP_001084026.1 | |
| 1036617–1038800 | 2,184 | A1S_0896 | YP_001083930.1 | |
| A1S_0897 | YP_001083931.1 | |||
| 3259867–3260118 | 252 | A1S_2814 | YP_001085822.1 | |
| 3260253–3260606 | 354 | A1S_2815 | YP_001085823.1 |
A. baumannii strain 19606.
FIG 1 Schematic diagram of the one-step recombineering method. Primers containing 125-bp homology flanking the gene of interest are used to amplify the PCR product. The insert is then recombined into the genome using our RecAb system. Screening primers outside the region of homology are used to confirm insertion of the kanamycin cassette.
FIG 2 PCR verification of constructed mutants. (A) Following recombineering, PCR was used to verify the presence of the wild-type allele or the replacement of that allele with a kanamycin resistance cassette to create the mutant strain. The wild-type control is marked “WT.” Shown are gene replacements with a kanamycin resistance cassette for targets lon, A1S_2456, aceI, and adeB. (B) Engineering of markerless mutants using the FLP-FRT recombination system. Lane 1, adeB wild type; lane 2, ΔadeB::FRT-Kanr strain; lane 3, ΔadeB strain after excision of the kanamycin resistance cassette; lane 4, lon wild type; lane 5, Δlon::FRT-Kanr strain; lane 6, Δlon strain after excision of the kanamycin resistance cassette. (C) Δlon::Kanr mutant of A. baumannii strain 19606. The 19606 strain wild-type control is marked “WT.”
FIG 3 Deletion of oxyR homolog A1S_0992 from A. baumannii results in increased sensitivity to hydrogen peroxide (H2O2). The parental A. baumannii strain and oxyR::Kanr mutant were struck on Luria-Bertani (LB) agar with or without 0.25 mM H2O2 (top). The oxyR::Kanr mutant H2O2 sensitivity phenotype is recovered by ectopic expression of the oxyR allele from a plasmid (p_oxyR) but not by the empty plasmid (pABBR_MCS) (bottom).
Chlorhexidine MICs
| Strain description | Chlorhexidine MIC (μg/ml) |
|---|---|
| Parental | 4 |
| Δ | 2 |
| Δ | 1 |
| Parental + empty vector | 4 |
| Δ | 2 |
| Δ | 1 |
| Δ | 4 |
| Δ | 2 |
| Δ | 1 |
| Δ | 0.5 |
A. baumannii 17978 carrying deletion of adeB after FRT-mediated excision of the kanamycin resistance cassette.
FIG 4 Biofilm formation assay of A. baumannii wild type, ΔpilUT::Kanr strain, ΔpilH::Kanr strain, and ΔpilG::Kanr strain, (A) Crystal violet staining of each strain in a PVC microtiter plate. (B) Biofilm formation measured by crystal violet staining for optical density at 540 nm (OD540). Asterisks denote significant differences in biofilm formation (t test; *, P < 0.0001; n = 8).
FIG 5 Transmission electron microscopy images of type IV pilus mutants of A. baumannii strain 17978. Black arrows specify pilus-like appendages. (A) Wild-type A. baumannii 17978; (B) ΔpilUT::Kanr strain; (C) ΔpilH::Kanr strain; (D) ΔpilG::Kanr strain.